Get the Stockscreener App
25.86
0.78%
0.20
Immunovant Inc stock is traded at $25.86, with a volume of 2.76M.
It is up +0.78% in the last 24 hours and down -1.18% over the past month.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
See More
Previous Close:
$25.66
Open:
$25.44
24h Volume:
2.76M
Relative Volume:
3.29
Market Cap:
$3.80B
Revenue:
-
Net Income/Loss:
$-323.01M
P/E Ratio:
-13.40
EPS:
-1.93
Net Cash Flow:
$-272.30M
1W Performance:
-1.60%
1M Performance:
-1.18%
6M Performance:
-5.24%
1Y Performance:
-28.52%
1-Day Range:
$25.25
$26.27
1-Week Range:
$25.25
$28.08
52-Week Range:
$24.61
$45.58
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
25.86 | 3.80B | 0 | -323.01M | -272.30M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Wells Fargo & Company Lowers Immunovant (NASDAQ:IMVT) Price Target to $45.00 - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.89 Consensus Target Price from Analysts - MarketBeat
Immunovant (NASDAQ:IMVT) Shares Down 5.2%Should You Sell? - MarketBeat
Immunovant's SWOT analysis: biotech stock poised for growth in Graves' disease - Investing.com India
State Street Corp Buys 303,386 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Head to Head Contrast: Jasper Therapeutics (NASDAQ:JSPR) versus Immunovant (NASDAQ:IMVT) - Defense World
The Manufacturers Life Insurance Company Has $1.05 Million Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Charles Schwab Investment Management Inc. Has $15.75 Million Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Redmile Group LLC Decreases Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant's SWOT analysis: stock undervalued amid promising Graves' disease treatment - Investing.com UK
Immunovant director Atul Pande sells shares for $221,185 By Investing.com - Investing.com Canada
Immunovant director Atul Pande sells shares for $221,185 - Investing.com
(IMVT) Investment Analysis and Advice - Stock Traders Daily
Bamco Inc. NY Sells 25,000 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Erste Asset Management GmbH Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Baker BROS. Advisors LP Raises Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Fmr LLC Increases Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Intech Investment Management LLC Buys Shares of 21,825 Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Algert Global LLC Sells 83,969 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Contrasting Immunovant (NASDAQ:IMVT) and enGene (NASDAQ:ENGN) - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Receives $48.10 Average Target Price from Analysts - Defense World
Have Immunovant Insiders Been Selling Stock? - Simply Wall St
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Buy" by Brokerages - MarketBeat
KBC Group NV Purchases 612 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Connor Clark & Lunn Investment Management Ltd. Sells 56,789 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Trend Tracker for (IMVT) - Stock Traders Daily
Immunovant, Inc. (NASDAQ:IMVT) CFO Sells $106,228.30 in Stock - MarketBeat
Insider Selling: Immunovant, Inc. (NASDAQ:IMVT) CEO Sells 16,692 Shares of Stock - MarketBeat
Immunovant CEO Peter Salzmann sells shares for $424,811 By Investing.com - Investing.com South Africa
Immunovant CFO Eva Renee Barnett sells $106,228 in stock By Investing.com - Investing.com South Africa
Immunovant CEO Peter Salzmann sells shares for $424,811 - Investing.com
Immunovant CFO Eva Renee Barnett sells $106,228 in stock - Investing.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Victory Capital Management Inc. - Defense World
Victory Capital Management Inc. Has $9.56 Million Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - MSN
Immunovant stock hits 52-week low at $24.66 amid market shifts - Investing.com Nigeria
Principal Financial Group Inc. Purchases 391,436 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Technical Data - Stock Traders Daily
FMR LLC's Strategic Acquisition of Immunovant Inc Shares - GuruFocus.com
Immunovant: Pipeline Progressing With One Minor Delay (NASDAQ:IMVT) - Seeking Alpha
Immunovant (NASDAQ:IMVT) Posts Earnings Results, Misses Expectations By $0.15 EPS - MarketBeat
Analysts Provide An Important Insights On Immunovant Inc (IMVT) - Stocks Register
Immunovant’s Strategic Advances in Autoimmune Therapies - TipRanks
Interesting IMVT Put And Call Options For March 2025 - Nasdaq
Immunovant's (IMVT) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Immunovant Inc (IMVT) Quarterly 10-Q Report - Quartzy
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hughes Douglas J. | Director |
Dec 02 '24 |
Sale |
28.54 |
5,425 |
154,830 |
119,585 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):